Roxadustat and thyroid-stimulating hormone suppression.
end-stage renal disease
hemodialysis
hypothyroidism
hypoxia-inducible factor prolyl-hydroxylase inhibitor
levothyroxine sodium hydrate
roxadustat
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
09
11
2020
accepted:
11
01
2021
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
epublish
Résumé
Hypoxia-inducible factor prolyl-hydroxylase inhibitors belong to a new class of orally administered drugs for treating anemia in patients with chronic kidney disease (CKD). The prevalence of hypothyroidism is disproportionately high in patients with CKD on hemodialysis. We report a rapid suppression of thyroid-stimulating hormone (TSH) and decrease in free triiodothyronine (T3) and free tetraiodothyronine levels after switching from darbepoetin alfa to roxadustat in a hemodialysis patient with hypothyroidism on levothyroxine therapy. This was reversed after stopping roxadustat. Roxadustat has structural similarity with T3 and is a selective activating ligand for thyroid hormone receptor-β possibly suppressing TSH release.
Identifiants
pubmed: 33959275
doi: 10.1093/ckj/sfab007
pii: sfab007
pmc: PMC8087136
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1472-1474Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.
Références
iScience. 2019 Oct 25;20:489-496
pubmed: 31655060
Nephrol Dial Transplant. 2015 Oct;30(10):1665-73
pubmed: 26238121
Nat Rev Nephrol. 2013 May;9(5):291-301
pubmed: 23438972
N Engl J Med. 1999 Apr 8;340(14):1075-9
pubmed: 10194237
Proc Natl Acad Sci U S A. 2016 May 3;113(18):E2516-25
pubmed: 27091985